Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Other: 2017-2025

Historic Receivables - Other for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $6.3 million.

  • Crinetics Pharmaceuticals' Receivables - Other rose 87.96% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 87.96%. This contributed to the annual value of $8.3 million for FY2024, which is 172.37% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Receivables - Other of $6.3 million as of Q3 2025, which was down 24.35% from $8.4 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Receivables - Other ranged from a high of $8.4 million in Q2 2025 and a low of $85,000 during Q1 2021.
  • In the last 3 years, Crinetics Pharmaceuticals' Receivables - Other had a median value of $3.4 million in 2024 and averaged $4.4 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Receivables - Other slumped by 38.85% in 2021 and then soared by 1,529.07% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Receivables - Other (Quarterly) stood at $553,000 in 2021, then spiked by 144.67% to $1.4 million in 2022, then spiked by 125.50% to $3.1 million in 2023, then spiked by 172.37% to $8.3 million in 2024, then skyrocketed by 87.96% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $8.4 million for Q2 2025, and $7.2 million during Q1 2025.